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Metabolic Syndrome, Gut Microbiome and Dietary
Bioactive Peptides, an Unexplored Triad
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ABSTRACT
The gut microbiome is a complex, biochemically rich and essential
component of the human metabolic system. It has been our
understanding for very long that the gut microbes are primarily there
to digest the undigested food (mainly fibers), get nourishment, and
in return release metabolites helping host cells — short-chain fatty
acids produced by gut microbes are a great source of energy for the
colonocytes. It is only in the last decade, with advancements of DNA

sequencing platforms, that we are lettered about the association
between the gut microbial composition and metabolic disorders such
as obesity, dysglycemia, dyslipidemia, and cardiovascular diseases.
This creates a momentum to understand the factors shaping the
composition of the gut-microbiome, nature of dysbiosis (perturbation
of gut microbial composition) associated with human health and ways
to modulate the gut microbiome to achieve the desired health benefits
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GUT MICROBIOME AND METABOLIC
SYNDROME
The gut microbiome is a complex, biochemically rich
and essential component of the human metabolic
system.1 It has been our understanding for very long
that the gut microbes are primarily there to digest the
undigested food (mainly fibers), get nourishment,
and in return release metabolites helping host cells —
short-chain fatty acids produced by gut microbes are
a great source of energy for the colonocytes.2,3,4 It is
only in the last decade, with advancements of DNA
sequencing platforms, that we are lettered about the
association between the gut microbial composition
and metabolic disorders such as obesity, dysglycemia, dyslipidemia, and cardiovascular diseases.5,6,7
This creates a momentum to understand the factors
shaping the composition of the gut-microbiome,
nature of dysbiosis (perturbation of gut microbial
composition) associated with human health and
ways to modulate the gut microbiome to achieve the
desired health benefits.8,9,10

DIET, A PREDOMINANT FACTOR
SHAPING THE GUT MICROBIOME
Since microbes colonize gut mainly for nutrients,
diet was hypothesized to be one of the predominant
factors shaping the gut microbial composition. In

last few years, this hypothesis was tested by multiple
individual groups and reported a direct association
between specific diet-types and gut microbial composition.1,11,12,13,14 Jansson/Tanja et al15 have found that
a diet rich in resistant starch (RS) modulates the
Firmicutes and Bacteroidetes ratio. A comparison
of animal and plant based diet has shown that even
a short term perturbation of diet may change the
composition of the gut microbiome, and animalbased diet boosts the abundance of bile-tolerant
microbes and decreases Firmicutes which uses
polysaccharides from plant sources.16 Similar observation of quick changes in microbial composition
has been found through the Western-diet (high Fat
and Sugar).17 Therefore, a dietary modulation of
gut-microbiome to treat above discussed metabolic
disorders is an experimental hypothesis tested at the
limited scale by several independent labs. A majority of these dietary interventions were about feeding
prebiotics, which is described as the food supplements for the gut microbiome. Typically fibers, indigestible to host, are used as prebiotics and have been
found to have positive impact on specific members
of gut-microbiome.18,19,20

BIOACTIVE DIETARY MOLECULES
Food is obviously our prime source of essential nutrients and plays a predominant role in
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determining our health status. While existing literature has a comprehensive report about the health
benefits of various food articles, our knowledge
about the molecular-mechanisms exerting these
benefits is still at its infancy. Advanced techniques
such as Next generation sequencing, has certainly
helped us untangle the complex association between
diet and the gut microbiome, which consequently
affects the physiological state of the human being.
One of the these less explored class of bioactive
molecules and molecular-mechanisms are dietary
peptides and their mode of action.

Bioactive peptides:
Bioactive peptides are part of scientific exploration
since the last three decades; and almost all levels of
living entities such as microbes, plants, and animals
either produce or have proteins that are digested
to bioactive peptides by proteases.21 For example,
serum albumin treated with trypsin produces
peptides with antihypertensive and antioxidant
activities, similarly plant sources such as wheat, rice,
oat, sorghum etc. were reported to be rich sources
of bioactive peptides.22,23 There are several reports of
milk and other dairy products as a reservoir of bioactive peptides.24,25 The range of activities of known
bioactive peptides are comprised of antihypertensive, antioxidant, anti-inflammatory and antimicrobial actions.26,27 Among these, the antimicrobial
activity of bioactive peptides draws a lot of attention,
as the frequency of microbial resistance to known
drugs is increasing. Antimicrobial peptides (AMP)
originated from the animal system are considered
as the first line of defence in the area with constant
exposure to pathogenic microbes. AMPs are natural
product of several prokaryotes and eukaryotes and
so far more than 5000 such peptides are reported
in the literature.28,29,30 The most common mode
of action of AMPs is dependent on their ability to
interact with the negatively charged cell surface of
the microbes and then insert into the hydrophobic
cell membrane and disrupt it either by creating pores
or making clusters. There is another class of AMPs
which are absorbed (cell penetration or endocytosis)
by the microbial cells and exert their activities by
disrupting essential biochemical pathways.31,32,33,34
Antimicrobial peptides with intracellular
activities
Beyond the common perception of antimicrobial
peptides acting as microbial cell-surface disrupter,
there is ample evidence of peptides with intracellular activities.32,33,34 Following are examples of antimicrobial peptides with intracellular activities:
Buforin I/II: Buforin-I is a 39 amino-acid long
AMP derived from the stomach of the Bufo bufo
2
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gargarizans, an Asian toad.35 While Buforin-I
has a broad spectrum antimicrobial activity, its
21 amino-acid long derivative (Buforin-II) was
found to be more potent. Contrary to the majority
of known AMPs, Bufroin-I/II interacts with DNA
& RNA to kill the microbes.36
Apidaecin type peptides: These peptides are
generally 18-20 amino acids long and were isolated
from honeybees.37,38 Predominantly uptaken
through the ABC transporters of Gram-negative
bacteria, Apidaecin peptides bind to ribosomes to
disrupt bacterial protein synthesis.39
Bac7: A 60 amino-acids long peptide derived
from the bovine neutrophils. Bac7 does not disrupt
bacterial cell membrane, but rather travels to the
cytoplasm with the help of peptide transporter
protein Sbm-A. Bac7 kills bacterial cells by targeting ribosomes and hindering protein synthesis.40
Indolicidin: It is a 13 amino-acids long peptide
derived from the bovine neutrophils. It interacts
with double stranded DNA molecules to arrest
transcription, replication and consequently kills the
bacterial cell.41,42

PEPTIDES AS NATURAL INHIBITORS
OF PROTEIN-PROTEIN INTERACTIONS
(PPIS)
As discussed above, there are several yet to be
defined biochemical interactions or ’mode of
actions’ of bioactive peptides — competitive inhibition of vital protein-protein interactions is one
of them. Protein-protein interactions (PPI) are
essential to most of the vital cellular-pathways such
as transcription, translation, signal transduction,
host-pathogen interactions, etc.,43 and are emerging as a new class of drug targets. Thus, recently
we have seen a wider effort to develop an array
of PPI inhibitors (antibodies, small-ligands and
peptides)44,45,46 and extend the concept to develop
microbial PPI inhibitors as a new class of antimicrobial agents.
Cellular protein-protein interaction networks are
marked by the presence of hub proteins — proteins
which interact with multiple individual proteins.
Such proteins are vital to entire networks, and consequently are prime targets for the antimicrobial agents.
Protein-protein complexes are characterized by
larger interfaces, where the interactions are mediated
by several short fragments (peptides). Few of these
interfacial peptides called hot-segments, contribute
most to the total binding energy of these complexes.
The hot-segments are used as 
lead-molecules to
develop new PPI inhibitors.47,48,49 Few of the several
such successful cases are inhibitory peptides for P53
& MDM250 and XIAP & Smac interactions;51 there
www.diabesity.ejournals.ca
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are also instances of peptides inhibiting oligomerization of membrane proteins.52,53
4.

TRIAD OF METABOLIC DISORDERS,
GUT MICROBIOME AND DIETARY
PEPTIDES
While a majority of dietary peptides are fully
digested and absorbed in the small intestine, there
is a significant fraction which escapes and reaches
the large intestine (a major reservoir of the gut
microbes) to either further be digested by microbial
enzymes or engulfed by them. As detailed above,
there are multiple instances of bacterial absorption of peptides leading to the inhibition of vital
microbial pathways and cell death. In the light of
this statement, it would be an intriguing thought
to evaluate the antimicrobial activity of dietary
peptides reaching the large intestine.
Given the the ability of peptides, sharing sequence
identity with hot-segments at protein-protein interfaces, to competitively inhibit PPI; we propose
an intriguing idea of exploring the interaction of
dietary peptides (peptides originating from digestion of dietary proteins in the human gastrointestinal tract) with gut microbes and test if such peptides
can be subcategorized as new class of antimicrobial
peptides. There are several unfathomed aspects of
these putative interactions, such as the optimum
length and composition of peptides for microbial
absorption or surface binding, minimum inhibitory
concentration of peptides, dietary proteins which are
a rich source of such bioactive peptides, and finally
fast and robust computational protocols to predict
bioactive peptides and evaluate their ability to inhibit
protein-protein interactions. We hope that with our
increasing understanding of the composition of the
gut microbiome and its association with human
health, there would be significant interest among the
scientific community about the interaction of gut
microbes and dietary peptides. A natural extension
of it would be the targeted dietary peptide based
modulation of the gut microbiome to treat metabolic
disorders. Authors, part of the current manuscript,
are currently performing in vitro experiments to
explore the absorption and microbial pathway inhibitory activities, of dietary peptides.
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